🇺🇸 Rabbit anti-thymocyte globulin in United States

13 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Respiratory Distress Syndrome — 3 reports (23.08%)
  2. Cytomegalovirus Infection — 2 reports (15.38%)
  3. Anaemia Of Chronic Disease — 1 report (7.69%)
  4. Aplasia Pure Red Cell — 1 report (7.69%)
  5. Aspergillosis — 1 report (7.69%)
  6. Bacterial Sepsis — 1 report (7.69%)
  7. Blood Creatinine Increased — 1 report (7.69%)
  8. Blood Stem Cell Transplant Failure — 1 report (7.69%)
  9. Bone Marrow Failure — 1 report (7.69%)
  10. Cardiac Arrest — 1 report (7.69%)

Source database →

Rabbit anti-thymocyte globulin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Rabbit anti-thymocyte globulin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Rabbit anti-thymocyte globulin in United States?

National Institute of Allergy and Infectious Diseases (NIAID) is the originator. The local marketing authorisation holder may differ — check the official source linked above.